|4Sep 5, 4:15 PM ET

Arbet-Engels Christophe 4

4 · X4 Pharmaceuticals, Inc · Filed Sep 5, 2023

Insider Transaction Report

Form 4
Period: 2023-08-31
Arbet-Engels Christophe
Chief Medical Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-08-31$1.28/sh+1,250,000$1,600,0001,250,000 total
    Exercise: $1.28Exp: 2033-08-30Common Stock (1,250,000 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to the option shall vest on August 31, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.

Documents

1 file
  • 4
    wk-form4_1693944923.xmlPrimary

    FORM 4